Phase 2 Trial Evaluates NEXIRI Regimen for Heavily Pretreated KRAS Mutation-positive mCRC

Share this content:
Sorafenib plus irinotecan (NEXIRI) is efficacious for the treatment of patients with refractory KRAS mutation-positive metastatic colorectal cancer.
Sorafenib plus irinotecan (NEXIRI) is efficacious for the treatment of patients with refractory KRAS mutation-positive metastatic colorectal cancer.

Sorafenib plus irinotecan (NEXIRI) is efficacious for the treatment of patients with refractory KRAS mutation-positive metastatic colorectal cancer (mCRC), a study presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco, CA, has shown.1

Because the NEXIRI regimen demonstrated promising activity with a disease control rate of 65% in heavily pretreated patients with mutated KRAS mCRC in a phase 1/2 study, researchers sought to determine the 2-month progression-free survival rate of NEXIRI compared with irinotecan or sorafenib monotherapy in this patient population.

For the study, researchers enrolled 173 patients with progressive measurable and non-resectable mutant KRAS mCRC with an ECOG performance status of 0 or 1 who were refractory to irinotecan, oxaliplatin, fluoropyrimidines, and bevacizumab.

Participants were randomly assigned 1:1:1 to receive irinotecan 120 - 180 mg/m2 biweekly plus sorafenib 400 mg orally twice daily, irinotecan 180 mg/m2 alone, or sorafenib alone until disease progression or unacceptable toxicity. Patients in the monotherapy arms were eligible to crossover to NEXIRI at progression.

Results showed that the 2-year progression-free survival rate was 59% (95% CI, 39 - 66) with NEXIRI, 23% (95% CI, 10 - 33) with irinotecan, and 22% (95% CI, 8 - 30). The disease control rate was 59%, 25%, and 22%, respectively, with 4 patients in the NEXIRI arm achieving a partial response.

Researchers found that median progression-free survival was 3.7 months (95% CI, 2.2 - 4.9) in the combination group, 1.9 months (95% CI, 1.7 - 2.1) in the irinotecan arm, and 2.1 months (95% CI, 1.9 - 2.5) in the sorafenib alone group. Median overall survival was 7.0 months (95% CI, 5.8 - 9.4), 6.3 months (95% CI, 4.8 - 8), and 5.1 months (95% CI, 3.7 - 7.7), respectively.

RELATED: FOLFOX for Colorectal Cancer Patients With Low Absolute Neutrophil Counts

In terms of toxicity, grade 3 or 4 neutropenia occurred in 18% of NEXIRI patients compared with 6% of irinotecan patients and none in the sorafenib arm. A total of 26% of patients in the NEXIRI arm reported grade 3 or 4 diarrhea vs 7% each in both of the monotherapy arms. The rate of grade 3 or 4  hand-foot syndrome was similar in the NEXIRI and sorafenib arm (17% vs 16%, respectively).

“These results justify comparing this combination to regorafenib or [trifluridine/tipiracil] monotherapies in this population,” the authors concluded. “Ancillary studies are ongoing to identify biomarkers.”

Reference

  1. Samalin E, De La Fouchardiere C, Thezanas S, et al. Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2) [abstract]. J Clin Oncol. 2016;34(suppl 4S; abstr 635).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters